Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MICHAEL FRUMOVITZ and SHANNON NEVILLE WESTIN.
MICHAEL FRUMOVITZ
Connection Strength
2.505
SHANNON NEVILLE WESTIN
  1. Neuroendocrine neoplasms of the ovary: a review of 63 cases. Int J Gynecol Cancer. 2024 Apr 01; 34(4):566-573.
    View in: PubMed
    Score: 0.246
  2. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623.
    View in: PubMed
    Score: 0.233
  3. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.206
  4. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575.
    View in: PubMed
    Score: 0.189
  5. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
    View in: PubMed
    Score: 0.176
  6. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.167
  7. Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard? J Minim Invasive Gynecol. 2016 Feb 01; 23(2):186-93.
    View in: PubMed
    Score: 0.137
  8. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
    View in: PubMed
    Score: 0.135
  9. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4.
    View in: PubMed
    Score: 0.127
  10. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
    View in: PubMed
    Score: 0.125
  11. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 Jan 06.
    View in: PubMed
    Score: 0.060
  12. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
    View in: PubMed
    Score: 0.057
  13. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
    View in: PubMed
    Score: 0.056
  14. An Integrated Approach to Selecting a Prepared Medical Decision-Maker. J Pain Symptom Manage. 2021 06; 61(6):1305-1310.
    View in: PubMed
    Score: 0.049
  15. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer. 2020 03; 30(3):352-357.
    View in: PubMed
    Score: 0.046
  16. Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. J Oncol Pract. 2019 12; 15(12):e1092-e1097.
    View in: PubMed
    Score: 0.045
  17. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353.
    View in: PubMed
    Score: 0.044
  18. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol. 2018 Sep; 29(5):e68.
    View in: PubMed
    Score: 0.041
  19. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.038
  20. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44.
    View in: PubMed
    Score: 0.034
  21. Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer. 2015 Sep; 25(7):1292-9.
    View in: PubMed
    Score: 0.034
  22. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015 Jan; 136(1):48-53.
    View in: PubMed
    Score: 0.032
  23. Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes? Gynecol Oncol. 2014 Aug; 134(2):248-52.
    View in: PubMed
    Score: 0.031
  24. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):366-71.
    View in: PubMed
    Score: 0.030
  25. Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecol Oncol. 2014 Jan; 132(1):114-8.
    View in: PubMed
    Score: 0.030
  26. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecol Oncol. 2013 Dec; 131(3):730-3.
    View in: PubMed
    Score: 0.030
  27. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol. 2013 Jun; 129(3):580-5.
    View in: PubMed
    Score: 0.028
  28. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol. 2012 May; 125(2):336-42.
    View in: PubMed
    Score: 0.026
  29. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.
    View in: PubMed
    Score: 0.026
  30. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol. 2011 Nov; 123(2):333-6.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.